Do analysts recommend DCTH or FONR?

Delcath Systems presently has a consensus price target of $22.50, indicating a potential upside of 70.45%. Given Delcath Systems' stronger consensus rating and higher possible upside, research analysts clearly believe Delcath Systems is more favorable than Fonar. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Delcath Systems 2 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.43 Fonar 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has better earnings and valuation, DCTH or FONR?

Fonar has higher revenue and earnings than Delcath Systems. Fonar is trading at a lower price-to-earnings ratio than Delcath Systems, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Delcath Systems $85.23M 5.35 $2.70M $0.01 1,320.00 Fonar $105.34M 1.12 $8.33M $1.00 19.09

Is DCTH or FONR more profitable?

Fonar has a net margin of 6.35% compared to Delcath Systems' net margin of 0.62%. Fonar's return on equity of 4.12% beat Delcath Systems' return on equity. Company Net Margins Return on Equity Return on Assets Delcath Systems 0.62% 0.51% 0.46% Fonar 6.35% 4.12% 3.07%

Do analysts prefer SI or FONR?

Shoulder Innovations presently has a consensus price target of $21.00, suggesting a potential downside of 0.74%. Given Shoulder Innovations' stronger consensus rating and higher possible upside, equities analysts plainly believe Shoulder Innovations is more favorable than Fonar. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Shoulder Innovations 1 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.57 Fonar 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00

Do analysts prefer FONR or CV?

CapsoVision has a consensus price target of $8.50, suggesting a potential upside of 16.76%. Given CapsoVision's stronger consensus rating and higher possible upside, analysts clearly believe CapsoVision is more favorable than Fonar. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Fonar 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 CapsoVision 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.50

Which has better valuation & earnings, FONR or CV?

Fonar has higher revenue and earnings than CapsoVision. CapsoVision is trading at a lower price-to-earnings ratio than Fonar, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Fonar $105.34M 1.12 $8.33M $1.00 19.09 CapsoVision $13.55M 26.84 -$25.32M -$2.34 N/A

Is FONR or CV more profitable?

Fonar has a net margin of 6.35% compared to CapsoVision's net margin of -198.87%. Fonar's return on equity of 4.12% beat CapsoVision's return on equity. Company Net Margins Return on Equity Return on Assets Fonar 6.35% 4.12% 3.07% CapsoVision -198.87% N/A -136.03%

Do analysts prefer ELMD or FONR?

Electromed currently has a consensus price target of $37.50, indicating a potential downside of 17.46%. Given Electromed's stronger consensus rating and higher probable upside, analysts plainly believe Electromed is more favorable than Fonar. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Electromed 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.25 Fonar 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has higher earnings and valuation, ELMD or FONR?

Fonar has higher revenue and earnings than Electromed. Fonar is trading at a lower price-to-earnings ratio than Electromed, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Electromed $71.75M 5.24 $5.15M $1.17 38.83 Fonar $105.34M 1.12 $8.33M $1.00 19.09

Is ELMD or FONR more profitable?

Electromed has a net margin of 11.34% compared to Fonar's net margin of 6.35%. Electromed's return on equity of 15.71% beat Fonar's return on equity. Company Net Margins Return on Equity Return on Assets Electromed 11.34% 15.71% 13.37% Fonar 6.35% 4.12% 3.07%

Do analysts rate SGHT or FONR?

Sight Sciences currently has a consensus price target of $8.14, suggesting a potential upside of 49.43%. Given Sight Sciences' stronger consensus rating and higher possible upside, analysts plainly believe Sight Sciences is more favorable than Fonar. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sight Sciences 1 Sell rating(s) 3 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.44 Fonar 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has preferable earnings & valuation, SGHT or FONR?

Fonar has higher revenue and earnings than Sight Sciences. Sight Sciences is trading at a lower price-to-earnings ratio than Fonar, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Sight Sciences $77.36M 3.83 -$38.43M -$0.71 N/A Fonar $105.34M 1.12 $8.33M $1.00 19.09

Is SGHT or FONR more profitable?

Fonar has a net margin of 6.35% compared to Sight Sciences' net margin of -46.83%. Fonar's return on equity of 4.12% beat Sight Sciences' return on equity. Company Net Margins Return on Equity Return on Assets Sight Sciences -46.83% -52.34% -28.49% Fonar 6.35% 4.12% 3.07%

Fonar (FONR) Competitors

$19.09 0.00 (0.00%)

As of 06/5/2026

Compare

FONR vs. DCTH, SI, CV, ELMD, and SGHT

Should you buy Fonar stock or one of its competitors? MarketBeat compares Fonar with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Fonar include Delcath Systems (DCTH), Shoulder Innovations (SI), CapsoVision (CV), Electromed (ELMD), and Sight Sciences (SGHT). These companies are all part of the "medical equipment" industry.

How does Fonar compare to Delcath Systems?

Delcath Systems (NASDAQ:DCTH) and Fonar (NASDAQ:FONR) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, institutional ownership, valuation, earnings, dividends and media sentiment.

Fonar has higher revenue and earnings than Delcath Systems. Fonar is trading at a lower price-to-earnings ratio than Delcath Systems, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Delcath Systems	$85.23M	5.35	$2.70M	$0.01	1,320.00
Fonar	$105.34M	1.12	$8.33M	$1.00	19.09

Fonar has a net margin of 6.35% compared to Delcath Systems' net margin of 0.62%. Fonar's return on equity of 4.12% beat Delcath Systems' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Delcath Systems	0.62%	0.51%	0.46%
Fonar	6.35%	4.12%	3.07%

61.1% of Delcath Systems shares are owned by institutional investors. Comparatively, 50.6% of Fonar shares are owned by institutional investors. 19.4% of Delcath Systems shares are owned by insiders. Comparatively, 7.9% of Fonar shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Delcath Systems has a beta of 0.49, meaning that its share price is 51% less volatile than the broader market. Comparatively, Fonar has a beta of 0.95, meaning that its share price is 5% less volatile than the broader market.

In the previous week, Delcath Systems' average media sentiment score of 0.00 equaled Fonar'saverage media sentiment score.

Company	Overall Sentiment
Delcath Systems	Neutral
Fonar	Neutral

Delcath Systems presently has a consensus price target of $22.50, indicating a potential upside of 70.45%. Given Delcath Systems' stronger consensus rating and higher possible upside, research analysts clearly believe Delcath Systems is more favorable than Fonar.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Delcath Systems	2 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.43
Fonar	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Delcath Systems and Fonar tied by winning 7 of the 14 factors compared between the two stocks.

How does Fonar compare to Shoulder Innovations?

Shoulder Innovations (NYSE:SI) and Fonar (NASDAQ:FONR) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, media sentiment, valuation, profitability, analyst recommendations, earnings and dividends.

In the previous week, Shoulder Innovations had 2 more articles in the media than Fonar. MarketBeat recorded 2 mentions for Shoulder Innovations and 0 mentions for Fonar. Shoulder Innovations' average media sentiment score of 0.62 beat Fonar's score of 0.00 indicating that Shoulder Innovations is being referred to more favorably in the media.

Company	Overall Sentiment
Shoulder Innovations	Positive
Fonar	Neutral

Fonar has higher revenue and earnings than Shoulder Innovations. Shoulder Innovations is trading at a lower price-to-earnings ratio than Fonar, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Shoulder Innovations	$47.32M	9.27	-$40.36M	-$166.96	N/A
Fonar	$105.34M	1.12	$8.33M	$1.00	19.09

50.6% of Fonar shares are owned by institutional investors. 29.0% of Shoulder Innovations shares are owned by company insiders. Comparatively, 7.9% of Fonar shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Shoulder Innovations presently has a consensus price target of $21.00, suggesting a potential downside of 0.74%. Given Shoulder Innovations' stronger consensus rating and higher possible upside, equities analysts plainly believe Shoulder Innovations is more favorable than Fonar.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Shoulder Innovations	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Fonar	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Fonar has a net margin of 6.35% compared to Shoulder Innovations' net margin of -81.78%. Fonar's return on equity of 4.12% beat Shoulder Innovations' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Shoulder Innovations	-81.78%	-35.11%	-20.58%
Fonar	6.35%	4.12%	3.07%

Summary

Fonar beats Shoulder Innovations on 8 of the 15 factors compared between the two stocks.

How does Fonar compare to CapsoVision?

Fonar (NASDAQ:FONR) and CapsoVision (NASDAQ:CV) are both small-cap medical equipment companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, risk, valuation, profitability, analyst recommendations, dividends, earnings and institutional ownership.

50.6% of Fonar shares are owned by institutional investors. 7.9% of Fonar shares are owned by company insiders. Comparatively, 2.3% of CapsoVision shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Fonar has higher revenue and earnings than CapsoVision. CapsoVision is trading at a lower price-to-earnings ratio than Fonar, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fonar	$105.34M	1.12	$8.33M	$1.00	19.09
CapsoVision	$13.55M	26.84	-$25.32M	-$2.34	N/A

CapsoVision has a consensus price target of $8.50, suggesting a potential upside of 16.76%. Given CapsoVision's stronger consensus rating and higher possible upside, analysts clearly believe CapsoVision is more favorable than Fonar.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fonar	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
CapsoVision	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50

In the previous week, CapsoVision had 3 more articles in the media than Fonar. MarketBeat recorded 3 mentions for CapsoVision and 0 mentions for Fonar. CapsoVision's average media sentiment score of 0.25 beat Fonar's score of 0.00 indicating that CapsoVision is being referred to more favorably in the news media.

Company	Overall Sentiment
Fonar	Neutral
CapsoVision	Neutral

Fonar has a net margin of 6.35% compared to CapsoVision's net margin of -198.87%. Fonar's return on equity of 4.12% beat CapsoVision's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Fonar	6.35%	4.12%	3.07%
CapsoVision	-198.87%	N/A	-136.03%

Summary

Fonar beats CapsoVision on 8 of the 15 factors compared between the two stocks.

How does Fonar compare to Electromed?

Electromed (NYSE:ELMD) and Fonar (NASDAQ:FONR) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, media sentiment, institutional ownership, earnings, risk, valuation, dividends and analyst recommendations.

Electromed has a beta of 0.5, suggesting that its share price is 50% less volatile than the broader market. Comparatively, Fonar has a beta of 0.95, suggesting that its share price is 5% less volatile than the broader market.

Fonar has higher revenue and earnings than Electromed. Fonar is trading at a lower price-to-earnings ratio than Electromed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Electromed	$71.75M	5.24	$5.15M	$1.17	38.83
Fonar	$105.34M	1.12	$8.33M	$1.00	19.09

Electromed currently has a consensus price target of $37.50, indicating a potential downside of 17.46%. Given Electromed's stronger consensus rating and higher probable upside, analysts plainly believe Electromed is more favorable than Fonar.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Electromed	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	3.25
Fonar	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Electromed's average media sentiment score of 0.00 equaled Fonar'saverage media sentiment score.

Company	Overall Sentiment
Electromed	Neutral
Fonar	Neutral

Electromed has a net margin of 11.34% compared to Fonar's net margin of 6.35%. Electromed's return on equity of 15.71% beat Fonar's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Electromed	11.34%	15.71%	13.37%
Fonar	6.35%	4.12%	3.07%

40.8% of Electromed shares are held by institutional investors. Comparatively, 50.6% of Fonar shares are held by institutional investors. 10.5% of Electromed shares are held by company insiders. Comparatively, 7.9% of Fonar shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Electromed beats Fonar on 11 of the 15 factors compared between the two stocks.

How does Fonar compare to Sight Sciences?

Sight Sciences (NASDAQ:SGHT) and Fonar (NASDAQ:FONR) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, valuation, dividends, profitability, earnings, institutional ownership and risk.

Sight Sciences currently has a consensus price target of $8.14, suggesting a potential upside of 49.43%. Given Sight Sciences' stronger consensus rating and higher possible upside, analysts plainly believe Sight Sciences is more favorable than Fonar.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sight Sciences	1 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.44
Fonar	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Sight Sciences had 1 more articles in the media than Fonar. MarketBeat recorded 1 mentions for Sight Sciences and 0 mentions for Fonar. Sight Sciences' average media sentiment score of 0.00 equaled Fonar'saverage media sentiment score.

Company	Overall Sentiment
Sight Sciences	Neutral
Fonar	Neutral

Fonar has higher revenue and earnings than Sight Sciences. Sight Sciences is trading at a lower price-to-earnings ratio than Fonar, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sight Sciences	$77.36M	3.83	-$38.43M	-$0.71	N/A
Fonar	$105.34M	1.12	$8.33M	$1.00	19.09

Fonar has a net margin of 6.35% compared to Sight Sciences' net margin of -46.83%. Fonar's return on equity of 4.12% beat Sight Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sight Sciences	-46.83%	-52.34%	-28.49%
Fonar	6.35%	4.12%	3.07%

Sight Sciences has a beta of 2.38, meaning that its stock price is 138% more volatile than the broader market. Comparatively, Fonar has a beta of 0.95, meaning that its stock price is 5% less volatile than the broader market.

55.5% of Sight Sciences shares are held by institutional investors. Comparatively, 50.6% of Fonar shares are held by institutional investors. 28.9% of Sight Sciences shares are held by company insiders. Comparatively, 7.9% of Fonar shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Sight Sciences beats Fonar on 8 of the 15 factors compared between the two stocks.

Get Fonar News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding FONR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

FONR vs. The Competition

Export

Metric	Fonar	MED PRODUCTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$117.84M	$8.77B	$7.17B	$12.48B
Dividend Yield	N/A	2.45%	2.66%	6.52%
P/E Ratio	19.09	13.34	23.43	22.41
Price / Sales	1.12	7.46	535.17	98.72
Price / Cash	9.09	18.40	29.65	49.23
Price / Book	0.74	3.55	10.97	6.49
Net Income	$8.33M	$226.17M	$3.57B	$336.25M
7 Day Performance	N/A	1.50%	2.12%	1.69%
1 Month Performance	N/A	-0.23%	5.25%	3.81%
1 Year Performance	20.79%	-0.49%	33.29%	23.90%

Fonar Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
FONR Fonar	2.3833 of 5 stars	$19.09 flat	N/A	N/A	$117.84M	$105.34M	19.09	480
DCTH Delcath Systems	1.6182 of 5 stars	$12.59 -2.8%	$22.50 +78.7%	+3.7%	$447.05M	$85.23M	1,259.00	60	Gap Down
SI Shoulder Innovations	2.2383 of 5 stars	$20.31 -3.7%	$21.00 +3.4%	N/A	$437.37M	$47.32M	N/A	61	Gap Down
CV CapsoVision	1.1367 of 5 stars	$7.58 +0.5%	$8.50 +12.1%	N/A	$376.73M	$13.55M	N/A	90	News Coverage
ELMD Electromed	0.6977 of 5 stars	$42.30 +0.2%	$37.50 -11.3%	+118.6%	$350.24M	$71.75M	56.40	160	Gap Down High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:FONR) was last updated on 7/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Fonar (FONR) Competitors

FONR vs. DCTH, SI, CV, ELMD, and SGHT

How does Fonar compare to Delcath Systems?

Summary

How does Fonar compare to Shoulder Innovations?

Summary

How does Fonar compare to CapsoVision?

Summary

How does Fonar compare to Electromed?

Summary

How does Fonar compare to Sight Sciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FONR vs. The Competition

Fonar Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Fonar (FONR) Competitors

FONR vs. DCTH, SI, CV, ELMD, and SGHT

How does Fonar compare to Delcath Systems?

Which has better earnings and valuation, DCTH or FONR?

Is DCTH or FONR more profitable?

Do insiders & institutionals believe in DCTH or FONR?

Which has more volatility and risk, DCTH or FONR?

Does the media prefer DCTH or FONR?

Do analysts recommend DCTH or FONR?

Summary

How does Fonar compare to Shoulder Innovations?

Does the media favor SI or FONR?

Which has stronger earnings & valuation, SI or FONR?

Do insiders & institutionals have more ownership in SI or FONR?

Do analysts prefer SI or FONR?

Is SI or FONR more profitable?

Summary

How does Fonar compare to CapsoVision?

Do insiders & institutionals hold more shares of FONR or CV?

Which has better valuation & earnings, FONR or CV?

Do analysts prefer FONR or CV?

Does the media prefer FONR or CV?

Is FONR or CV more profitable?

Summary

How does Fonar compare to Electromed?

Which has more volatility and risk, ELMD or FONR?

Which has higher earnings and valuation, ELMD or FONR?

Do analysts prefer ELMD or FONR?

Does the media refer more to ELMD or FONR?

Is ELMD or FONR more profitable?

Do institutionals and insiders believe in ELMD or FONR?

Summary

How does Fonar compare to Sight Sciences?

Do analysts rate SGHT or FONR?

Does the media favor SGHT or FONR?

Which has preferable earnings & valuation, SGHT or FONR?

Is SGHT or FONR more profitable?

Which has more volatility and risk, SGHT or FONR?

Do institutionals & insiders hold more shares of SGHT or FONR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FONR vs. The Competition

Fonar Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools